Effects of colchicine on primary knee osteoarthritis

Primary tabs

Effects of colchicine on primary knee osteoarthritis

Knee osteoarthritis is a painful debilitating condition which arise due to gradual loss of cartilage from the joints and, in some people due to joint inflammation. It can affect any joint, with the most common one being in the hands, knees, hips, and spine. The patient also experiences stiffness and difficulty moving the joint smoothly. For treatment, colchicine is often advised for people with inflammatory OA that does not improve with non-pharmacologic therapies and NSAIDs. A clinician may suggest colchicine for people who have frequent flares of OA that is resistant to other treatments.

These research work mentioned here explains whether the therapeutic use of colchicine along with etodolac (selective COX-2 inhibitor) confer any significant effect in the treatment of osteoarthritis of knee joint.

For 26 weeks, 40 selected subjects were randomized to receive either 0.5 mg of colchicine twice daily or placebo. On day 0, weeks 2, 6, 10, 14, 18, 22 and 26, the visual analog scale (VAS), Western Ontario and McMaster University Osteoarthritis total scale (WOMAC), and patient global assessment and physician global assessment scores were noted down. The improvement rate at the end of 22 weeks was higher in colchicine group than placebo, as assessed by VAS score (46.88 vs.51.11; P=0.033), WOMAC score (18.88 vs.24.56; P=0.019), patient global assessment score (34.69 vs. 38.33; P=0.039) and physician global assessment [score (20.00 vs. 26.39; P=0.02).

Thus, it was inferred that the subjects obtaining colchicine plus etodolac revealed significantly better symptom control at the end of 22 weeks than the placebo group.


Internet Journal of Rheumatology and Clinical Immunology

Link to the source:


Original title of article:

The slow-acting, symptom modifying effects of colchicine in primary knee osteoarthritis


A Pandey et al.

Therapeutic, Colchicine, Etodolac, Osteoarthritis, Knee, NSAIDs, RCT, Efficacy, VAS, WOMAC
Log in or register to post comments